[1] |
|
[2] |
|
[3] |
MALLETT A, TANG W, CLAYTON P A,et al. End-stage kidney disease due to Alport syndrome:outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases[J]. Nephrol Dial Transplant, 2014, 29(12):2277-2286. DOI: 10.1093/ndt/gfu254.
|
[4] |
HATTORI M, SAKO M, KANEKO T,et al. End-stage renal disease in Japanese children:a nationwide survey during 2006-2011[J]. Clin Exp Nephrol, 2015, 19(5):933-938. DOI: 10.1007/s10157-014-1077-8.
|
[5] |
|
[6] |
MORINIÈRE V, DAHAN K, HILBERT P,et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing[J]. J Am Soc Nephrol, 2014, 25(12):2740-2751. DOI: 10.1681/ASN.2013080912.
|
[7] |
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD:2012 update[J]. Am J Kidney Dis, 2012, 60(5):850-886. DOI: 10.1053/j.ajkd.2012.07.005.
|
[8] |
EMBL-EBI. Protein:COL4A4_HUMAN(P53420)[EB/OL].[2022-05-01].
|
[9] |
RICHARDS S, AZIZ N, BALE S,et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424. DOI: 10.1038/gim.2015.30.
|
[10] |
FALLERINI C, DOSA L, TITA R,et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases[J]. Clin Genet, 2014, 86(3):252-257. DOI: 10.1111/cge.12258.
|
[11] |
|
[12] |
|
[13] |
LI A, GAO E Z, CUI Y X,et al. Three novel heterozygous COL4A4 mutations result in three different collagen type IV kidney disease phenotypes[J]. Cytogenet Genome Res, 2018, 154(1):30-36. DOI: 10.1159/000486979.
|
[14] |
GUO L W, LI D, DONG S S,et al. Mutation analysis of COL4A3 and COL4A4 genes in a Chinese autosomal-dominant Alport syndrome family[J]. J Genet, 2017, 96(2):389-392. DOI: 10.1007/s12041-017-0786-7.
|
[15] |
DENG S, XU H B, YUAN J Z,et al. Identification of a novel collagen type IV alpha-4(COL4A4)mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing[J]. Indian J Med Res, 2016, 144(2):200-205. DOI: 10.4103/0971-5916.195026.
|
[16] |
|
[17] |
|
[18] |
JEFFERSON J A, LEMMINK H H, HUGHES A E,et al. Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes(COL4A3 and COL4A4)[J]. Nephrol Dial Transplant, 1997, 12(8):1595-1599. DOI: 10.1093/ndt/12.8.1595.
|
[19] |
PESCUCCI C, MARI F, LONGO I,et al. Autosomal-dominant Alport syndrome:natural history of a disease due to COL4A3 or COL4A4 gene[J]. Kidney Int, 2004, 65(5):1598-1603. DOI: 10.1111/j.1523-1755.2004.00560.x.
|
[20] |
KAMIYOSHI N, NOZU K, FU X J,et al. Genetic,clinical,and pathologic backgrounds of patients with autosomal dominant alport syndrome[J]. Clin J Am Soc Nephrol, 2016, 11(8):1441-1449. DOI: 10.2215/CJN.01000116.
|
[21] |
FURLANO M, MARTÍNEZ V, PYBUS M,et al. Clinical and genetic features of autosomal dominant alport syndrome:a cohort study[J]. Am J Kidney Dis, 2021, 78(4):560-570.e1. DOI: 10.1053/j.ajkd.2021.02.326.
|
[22] |
MARCOCCI E, ULIANA V, BRUTTINI M,et al. Autosomal dominant Alport syndrome:molecular analysis of the COL4A4 gene and clinical outcome[J]. Nephrol Dial Transplant, 2009, 24(5):1464-1471. DOI: 10.1093/ndt/gfn681.
|
[23] |
|
[24] |
|
[25] |
陈中杰,张旭,林泽芬,等. Alport综合征的诊疗和管理研究进展[J]. 中华儿科杂志,2022,60(4):370-373.
|
[26] |
KASHTAN C E, GROSS O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children,adolescents,and young adults-an update for 2020[J]. Pediatr Nephrol, 2021, 36(3):711-719. DOI: 10.1007/s00467-020-04819-6.
|
[27] |
GROOPMAN E E, MARASA M, CAMERON-CHRISTIE S,et al. Diagnostic utility of exome sequencing for kidney disease[J]. N Engl J Med, 2019, 380(2):142-151. DOI: 10.1056/NEJMoa1806891.
|
[28] |
CAMERON-CHRISTIE S, WOLOCK C J, GROOPMAN E,et al. Exome-based rare-variant analyses in CKD[J]. J Am Soc Nephrol, 2019, 30(6):1109-1122. DOI: 10.1681/ASN.2018090909.
|